<DOC>
	<DOCNO>NCT01813318</DOCNO>
	<brief_summary>Recent pharmacotherapy research autism spectrum disorder ( ASD ) successfully focused treatment co-occurring symptom , include inattention , hyperactivity , irritability commonly occur person ASD . Despite two decade significant pharmacotherapy research , date medication show controlled trial enhance core social deficit ASD . Based upon finding describe neurobiology ASD combine preliminary result , believe novel drug acamprosate show evidence reduce social skill deficit associate ASD .</brief_summary>
	<brief_title>Study Acamprosate Autism</brief_title>
	<detailed_description>Each subject ASD receive 10 week blind treatment acamprosate match placebo . After completion double-blind phase , subject opportunity receive acamprosate part study procedures 16 week .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>517 yearold outpatient Diagnosis ASD General good health ( determine exam , history , laboratory work ) Use two concomitant psychotropic drug ( stable dose &gt; 60 day ) impact glutamate gammaaminobutyric acid A ( GABA ) neurotransmission allow Stable seizure disorder ( seizures 6 month ; anticonvulsant dose &gt; 60 day ) Clinical Global Impression Scale Severity score ( CGIS ) 4 ( Moderately III ) Score 13 Social Withdrawal subscale Aberrant Behavior Checklist ( ABCSW ) screen baseline Potential subject creatinine clearance &lt; 50 mL/min evidence previous trial acamprosate exclude</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>